Welcome to our dedicated page for Proto Labs SEC filings (Ticker: PRLB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Proto Labs, Inc. filings document the regulatory record for an NYSE-listed digital manufacturing company that produces custom parts for prototyping, testing, bridge production, short-run production, and end-use applications. Its SEC disclosures cover operating results, revenue by service activity, non-GAAP measures, cash-flow commentary, and business updates related to CNC machining, digital platforms, and manufacturing capacity.
PRLB filings also include Form 8-K material-event reports for earnings releases and executive leadership changes, amendments to previously furnished results information, and proxy materials covering board matters, executive compensation, equity awards, shareholder voting items, and governance. The company’s filings identify its common stock under the PRLB ticker on the New York Stock Exchange.
Proto Labs, Inc. announced an executive leadership transition. Chief Operations Officer Michael R. Kenison plans to retire effective July 1, 2026 after a long tenure helping expand the company’s global manufacturing footprint.
The company appointed Bernardo Parlange as its first Chief Commercial Officer, effective May 18, 2026. In this newly created role, he will lead global commercial strategy across sales, marketing, and customer success, with a focus on revenue growth, stronger strategic customer relationships, and enhancing the customer experience. These changes were detailed in an accompanying press release furnished as an exhibit.
Proto Labs, Inc. delivered stronger quarterly performance, with revenue rising to $139.3M from $126.2M, driven mainly by CNC machining and solid growth in both U.S. and European operations. Gross margin improved to 45.6%, reflecting higher volumes and pricing.
Net income more than doubled to $8.1M, with diluted EPS increasing to $0.33. Operating cash flow was $17.5M, and cash and cash equivalents grew to $124.0M, giving the company ample liquidity while it continues to invest in capacity, technology and stock-based incentive programs.
Proto Labs, Inc. reported strong first quarter 2026 results with record revenue of $139.3 million, up 10.4% from the first quarter of 2025. GAAP diluted earnings per share were $0.33, more than double the prior year’s $0.15, while non-GAAP diluted earnings per share rose to $0.54 from $0.33.
CNC machining revenue grew 19.7% year-over-year, and revenue per customer contact increased 20.4%, showing customers are spending more per order even as total contacts declined. Non-GAAP gross margin improved to 46.2% of revenue and Adjusted EBITDA margin increased to 16.3%, reflecting better profitability.
The company generated $17.5 million in cash from operations and held $158.0 million in cash and investments as of March 31, 2026. For full-year 2026, Proto Labs expects revenue growth between 6% and 8%. For the second quarter 2026, it forecasts revenue of $140.0–$148.0 million, GAAP diluted earnings per share of $0.29–$0.37, and non-GAAP diluted earnings per share of $0.50–$0.58.
Proto Labs Inc ownership filing shows Vanguard Capital Management beneficially owned 1,213,755 shares of Common Stock, equal to 5.1% of the class as of 03/31/2026. The filing lists sole voting power for 174,014 shares and sole dispositive power for 1,213,755 shares.
Proto Labs Inc ownership disclosure: Vanguard Portfolio Management reports beneficial ownership of 1,548,595 shares of Common Stock, representing 6.51% of the class as of 03/31/2026. The filing shows sole dispositive power over 1,548,595 shares and sole voting power for 10,065 shares. Vanguard states these holdings include securities held for Vanguard funds and managed accounts, with dispositive or voting power exercised by affiliated investment advisers.
Proto Labs, Inc. is asking shareholders to vote at its 2026 virtual annual meeting on May 19, 2026 to elect seven directors and approve several governance and pay matters. Proposals include ratifying Ernst & Young as auditor, an advisory say-on-pay vote, how often to hold future say-on-pay votes, and an amendment to the 2022 Long-Term Incentive Plan, all supported by the board.
The proxy highlights record 2025 revenue of $533.1 million, 6.4% above 2024, and non-GAAP diluted EPS of $1.66, slightly higher than 2024. Management emphasizes digital manufacturing capabilities, stronger revenue per customer contact, and a pay-for-performance philosophy with a mix of cash incentives and equity, including performance stock units tied to three-year total shareholder return.
The Vanguard Group filed an amended Schedule 13G/A for Proto Labs Inc. The amendment states that, following an internal realignment effective January 12, 2026, Vanguard and its reporting entities report zero beneficial ownership of Proto Labs common stock and list ownership as 0 shares (0%).
The filing explains certain Vanguard subsidiaries now report separately under SEC Release No. 34-39538 and affirms no single outside person holds more than 5% of the class. The amendment is signed by Vanguard's Head of Global Fund Administration on 03/27/2026.
Krishna Suresh reported acquisition or exercise transactions in this Form 4 filing.
Proto Labs Inc director and President & CEO Suresh Krishna reported equity awards on February 25, 2026. He received 24,383 employee stock options and a grant of 13,373 shares of common stock at a price of $0.00 per share as compensation awards. The related restricted stock units vest 25% on February 25, 2027 and on each February 25 thereafter until fully vested.
Proto Labs Inc Chief Financial Officer Daniel Schumacher reported equity compensation changes. He received a grant of 5,605 employee stock options and 3,074 shares of common stock, both at a price of $0.00 per share, increasing his direct holdings. A separate disposition of 504 common shares at $62.63 per share was made to cover tax withholding obligations, rather than an open-market sale. The restricted stock units underlying the common stock grant vest in four equal annual installments, with 25% vesting on February 25, 2027 and on each February 25 thereafter until fully vested.